Which is absolutely true...but those drugs are not exactly anywhere near the end of the pipeline. 530 rejected and must redo trials, 514 still in trials and no NDA ever submitted, 188 even earlier in the pipeline trials. No chance of revenue for a year - and that is absolute BEST case. Buyout is always the wildcard.